Growth hormone-releasing activity of hexarelin in humans
- 1 June 1994
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 46 (5) , 421-425
- https://doi.org/10.1007/bf00191904
Abstract
Hexarelin is a new hexapeptide (His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2) that stimulates the release of growth hormone both in vitro and in vivo. In this double-blind, placebo-controlled, rising-dose study we evaluated the growth hormone releasing activity of hexarelin in healthy human subjects. Twelve adult male volunteers received single intravenous boluses of 0.5, 1 and 2 ·μg·kg−1 hexarelin as well as placebo. For safety, drug doses were given in a rising-dose fashion with placebo randomly inserted into the sequence. Plasma growth hormone concentrations increased dose-dependently after the injection of the peptide, peaking at about 30 min and then decreasing to baseline values within 240 min with a half-life of about 55 min. The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng·ml−1 after 0, 0.5, 1 and 2 μg·kg−1, respectively. The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0–180) were 0.135, 1.412, 2.918 and 3.695 μg·min·ml−1. The theoretical maximum response (Emax) and the dose that produces half of the maximum response (ED50) were estimated using logistic regression. The calculated ED50 values were 0.50 and 0.64 μg·kg−1 for Cmax and AUC0–180, respectively. The corresponding Emaxs were 55.1 ng·ml−1 and 3936 ng·min·ml−1, thus indicating that the effect after the 2 μg·kg−1 dose is very close to the maximal response. Plasma glucose, luteinising hormone, follicle-stimulating hormone, thyroid-stimulating hormone and insulin-like growth factor I were unaffected by hexarelin administration, while the peptide caused a slight increase in prolactin, cortisol and adrenocorticotropic hormone levels. Hexarelin was well tolerated in all subjects. The results of this study indicate that intravenous administration of hexarelin in man produces a substantial and dose-dependent increase of growth hormone plasma concentrations.Keywords
This publication has 17 references indexed in Scilit:
- GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult ratsLife Sciences, 1994
- Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neuronsNeuroscience, 1993
- Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells.Endocrinology, 1993
- GH Releasing Peptides - Structure and KineticsJournal of Pediatric Endocrinology and Metabolism, 1993
- Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP‐6Clinical Endocrinology, 1993
- Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men.Journal of Clinical Endocrinology & Metabolism, 1992
- The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration.Journal of Clinical Endocrinology & Metabolism, 1992
- Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-d-Trp-Ala-Trp-d-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sitesJournal of Endocrinology, 1991
- Intranasal Administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (Growth Hormone Releasing Peptide) Increased Plasma Growth Hormone and Insulin-like Growth Factor-I Levels in Normal Men.Endocrinologia Japonica, 1991
- Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sitesNeuropharmacology, 1989